Pioneering Bispecific Single Domain Antibody (SdAb) Discovery Service

Workflow Bispecific SdAb Formats Services Application Advantage Related Services FAQ Online Inquiry

Fig. 1 Camel. (Creative Biolabs Authorized)

Single domain antibodies (SdAbs), also known as V_HH, have revolutionized antibody engineering due to their small size (~15 kDa), exceptional stability, high solubility, and ability to recognize unique epitopes. This dual functionality unlocks novel mechanisms of action that are unattainable with monospecific antibodies, opening new frontiers in oncology, immunology, neurodegenerative diseases, and beyond. At Creative Biolabs, we have spent over two decades mastering the complexities of antibody engineering. Our state-of-the-art Bispecific SdAb Platform integrates proprietary library construction techniques, advanced display technologies, and sophisticated protein engineering strategies to deliver custom BsSdAb candidates with unparalleled precision and speed.

Discuss Your Project Today

Our Advanced Bispecific SdAb Discovery Workflow

We have streamlined the discovery process into a transparent, phase-gated workflow. This ensures you are involved at every critical decision point and that the project progresses efficiently toward your desired endpoint.

Workflow Diagram: From Target to Validated BsSdAb Candidate

Phase 1: Project Consultation & Antigen Design
Phase 2: Camelid Immunization & Library Construction
Phase 3: High-Throughput Screening & Binder Identification
Phase 4: SdAb Sequencing, Expression & Characterization
Phase 5: Bispecific Design & Engineering
Phase 6: BsSdAb Expression & Purification
Phase 7: In-depth Functional & Biophysical Analysis
Phase 8: Lead Candidate Delivery & Reporting

Detailed Service Phases

Project Consultation and Antigen Strategy: We start with a deep dive into your project goals, target biology, and desired mechanism of action. Our experts will advise on the optimal antigen design (peptides, recombinant proteins, cell lines) to elicit a robust and diverse immune response.
Camelid Immunization and Library Construction: We perform immunization of llamas or alpacas using proprietary adjuvants and optimized schedules. Following immunization, we harvest peripheral blood mononuclear cells and construct high-diversity immune V_HH phage or yeast display libraries, capturing a repertoire of 10⁹ unique clones.
High-Throughput Screening (Biopanning): Using your target molecules, we perform multiple rounds of affinity-based screening (biopanning) to enrich for high-affinity and specific binders. Our ability to use phage display screening, yeast display screening, or mammalian display screening allows us to tailor the screening pressure for desired attributes like epitope specificity, cross-reactivity, or pH sensitivity.
Monospecific SdAb Candidate Validation: Positive clones are screened via high-throughput ELISA or FACS. Promising candidates are sequenced, expressed as monovalent SdAbs, and undergo preliminary characterization for affinity and specificity.
Bispecific Design and Engineering: This is where our expertise shines. Based on the validated monospecific SdAbs and your desired functionality, our scientists will design the optimal bispecific format. This includes selecting the orientation of the V_HH domains and choosing the appropriate linker to ensure proper folding and target engagement.
BsSdAb Expression and Purification: The engineered bispecific construct is cloned into our optimized expression vectors (bacterial or mammalian systems, e.g., E. coli, CHO, HEK293). We then perform small- to mid-scale expression and purify the BsSdAb to >95% purity using advanced chromatography techniques.
In-depth Functional and Biophysical Analysis: The purified BsSdAb is subjected to a comprehensive panel of assays to validate its structure and function.
Lead Candidate Delivery: You receive a comprehensive data package including the final report, purified BsSdAb protein samples, and complete sequence information for your lead candidates.

Flexible Bispecific SdAb Formats

The modular nature of SdAbs allows for the creation of numerous bispecific formats. We can engineer virtually any format to achieve your desired biological outcome.

Format	Schematic Representation	Key Features & Applications
Head-to-Tail Tandem	V_HH-A — Linker —V_HH-B	Most Common Format. Simple, robust, and highly expressible. Ideal for redirecting immune cells, blocking two pathways, or bridging molecules.
Bi-paratopic	V_HH-A1 — Linker —V_HH-A2	Targets two different, non-overlapping epitopes on the same antigen. Can lead to enhanced avidity, receptor clustering, or internalization.
Common-Chain (Central) V_HH	V_HH-A — Linker —V_HH-C — Linker —V_HH-B	A central V_HH (V_HH-C) is fused to two other V_HHs. Useful for creating more complex trivalent or tetravalent molecules.
Diabody-like Format	(V_HH-A)-( V_HH-B) Dimer	Formed by the non-covalent association of two V_HH-A—V_HH-B fusion chains. Can provide specific spatial arrangements of binding sites.
Custom Engineered Formats	Structure varies	We can incorporate Fc domains for extended half-life (V_HH-Fc- V_HH) or design novel architectures tailored to unique mechanisms of action.

Comprehensive Downstream Characterization Services

To ensure your bispecific candidate is ready for the next stage of development, we offer a full suite of analytical services:

Category	Specific Assays
Binding Affinity & Kinetics	Surface Plasmon Resonance (SPR), Biolayer Interferometry (BLI), Isothermal Titration Calorimetry (ITC), MicroScale Thermophoresis (MST)
Specificity & Epitope Binning	ELISA, Flow Cytometry (FACS), Competitive Sandwich Assays (SPR/BLI), Western Blot
Functional Activity	Cell-based Assays (e.g., T-cell redirection, receptor blocking, signaling pathway modulation), Enzyme Activity Assays
Biophysical Properties	Size Exclusion Chromatography (SEC-MALS), Dynamic Light Scattering (DLS), Circular Dichroism (CD), Differential Scanning Calorimetry (DSC) for thermal stability
Developability Assessment	Solubility Studies, Aggregation Propensity (DLS, SEC), Freeze-Thaw Stability, Serum Stability Assays

The Creative Biolabs Advantage in Bispecific SdAb Discovery

Partnering with us provides you access to an end-to-end solution, from initial concept to a fully characterized, lead-optimized bispecific molecule.

World-Class Expertise: Leverage our 20+ years of dedicated experience in antibody discovery and engineering. Our PhD-level scientists guide every project, ensuring scientific rigor and strategic alignment with your goals.
High-Diversity Libraries: We begin with exceptionally diverse camelid V_HH libraries, sourced from immunized llamas or alpacas, or our vast naïve libraries. This ensures the highest probability of discovering high-affinity binders against even the most challenging targets.
Multi-Platform Screening: We are not limited to a single technology. We employ a suite of powerful display platforms, including Phage Display, Yeast Display, and Mammalian Cell Display, to select the best possible SdAb candidates based on your project's specific needs.
Unrivaled Engineering Flexibility: Our protein engineering teams are adept at creating a wide array of BsSdAb formats. We use advanced molecular biology techniques to connect SdAb domains, optimizing for stability, functionality, and manufacturability.
Comprehensive Characterization: A discovered candidate is only as good as its characterization. We provide in-depth biophysical and functional analysis to ensure your final BsSdAb meets all critical quality attributes.

Applications of Bispecific Single Domain Antibodies

The unique properties of BsSdAbs make them ideal for a wide range of research and pre-clinical applications:

Oncology: Redirecting immune cells (e.g., T-cells, NK cells) to tumor cells, dual blockade of tumor growth pathways (e.g., HER2 & EGFR), targeting tumor microenvironment.
Immunology: Modulating immune responses by simultaneously engaging two different cytokine receptors or cell surface markers in autoimmune diseases.
Neuroscience: Designing blood-brain barrier (BBB) shuttles by combining a BBB receptor binder with a therapeutic binder for CNS targets.
Infectious Diseases: Neutralizing viruses or bacteria by targeting two distinct epitopes, preventing viral escape.
Diagnostics: Developing highly sensitive and specific sandwich immunoassays or imaging agents.

Related Featured SdAb Discovery Services

Explore our specialized services to advance your research:

Our experts are ready to discuss your project and design a custom SdAb discovery strategy.

Contact Us Today for a Free Quote!

Frequently Asked Questions (FAQ)

Q1: What are the main advantages of a bispecific SdAb over a full-size bispecific IgG?

A: BsSdAbs offer several key advantages: smaller size for better tissue penetration, higher stability and solubility, simpler and more cost-effective production (often in microbial systems), and the ability to access cryptic epitopes that are inaccessible to conventional IgGs.

Q2: How long does a typical BsSdAb discovery project take?

A: The timeline can vary based on project complexity, but a standard project from immunization to delivery of a characterized lead candidate typically takes 6-9 months.

Q3: Can you generate a bi-paratopic SdAb that targets two different epitopes on my protein of interest?

A: Absolutely. Our screening and engineering strategies are perfectly suited for discovering bi-paratopic antibodies. We can perform epitope binning assays to select two V_HHs that bind non-competitively to your target.

Q4: What if I already have a single domain antibody and need to make it bispecific?

A: We can certainly help. If you have the sequence of your existing SdAb, our team can engineer it into a bispecific format with one of our in-house V_HH binders or another SdAb you provide.

Reference

Toffoli, Elisa C., et al. "Enhancement of NK cell antitumor effector functions using a bispecific single domain antibody targeting CD16 and the epidermal growth factor receptor." Cancers 13.21 (2021): 5446. https://doi.org/10.3390/cancers13215446

×

Online Inquiry

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.